Natasha Jolakoski on Rethinking Lead-in Strategies in VTE
Natasha Jolakoski, PGY-2 Thrombosis and Hemostasis Resident at The University of New Mexico Hospital, shared on LinkedIn:
”I’m excited to share that our multicenter study, “Rethinking lead-in strategies: evaluation of full vs. reduced-dose factor Xa inhibitors in acute VTE,” has been published in the Journal of Thrombosis and Thrombolysis.
This study evaluated bleeding and thrombotic outcomes associated with reducing factor Xa inhibitor lead-in duration in patients who received prior parenteral anticoagulation, across 1,400+ patients with acute VTE.
We found that a reduced lead-in approach was not associated with higher rates of VTE recurrence or major bleeding.
I’d like to thank my preceptors, Stephanie Edwin and Christopher Giuliano , for their guidance and support throughout this project, as well as all the co-authors who made this collaboration possible.”
Read the full article here.
Article: Rethinking lead-in strategies: evaluation of full vs. reduced dose factor Xa inhibitors in acute VTE
Authors: Natasha Jolakoski, Sarah Grazia, Clare Brewster, Brehanna Edwards, Danielle Rosas, Diana Penev, Whitney Anderson, Stephanie B. Edwin, Shannon Carabetta, Bradley Haan, Thomas Breedan, Megan Laux, Kathaleen Watson, Andrew Harpenau, Rachel Bruns, Josephine Varda, Kathleen Koopman, Meagan Paylor, Christopher Guiliano
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 30, 2026, 11:38Aaron Rodriguez Calienes on Intracranial Stenting: Rescue vs First-Line Outcomes
-
Jan 30, 2026, 11:25Ahmed Nasreldein on Sex Disparities in Thrombolysis Delay Among Egyptian Stroke Patients
-
Jan 30, 2026, 11:17Yanki Yarman: My PhD Project Has Been Published in Blood!
-
Jan 30, 2026, 11:08Alexandros Apostolou on Complications Associated with IDU and Thrombophilia
-
Jan 30, 2026, 10:57Peisong Ma on GRK5 Polymorphism Affecting Platelets
-
Jan 30, 2026, 10:47Ashok Yadav Explains Fetal Thrombotic Vasculopathy: FTV
-
Jan 30, 2026, 10:34Saif ur Rahman Compares K2 and K3 EDTA: Key Differences Explained
-
Jan 30, 2026, 10:22Manpreet Gill on Heparin Resistance: When 14 Years of Experience Finally Gets a Plot Twist
-
Jan 30, 2026, 10:14Mohamed Elsaid on The Role of Hyperlipidemia in Thrombogenesis